Ibuprofen and cardiovascular safety: Where do we stand?

Journal of the Royal Society of Medicine, Supplement

Volumn 100, Issue 48, 2007, Pages 7-10

  Purcell, Henry ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; THROMBOXANE A2; VALDECOXIB;

ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; HUMANS; IBUPROFEN; RISK FACTORS;

EID: 38849105713     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Jones SF, Power I. Postoperative NSAIDs and COX-2 inhibitors: cardiovascular risks and benefits. Br J Anaesth 2005;95:281-4
2. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-13
3. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
5. Moien-Afshari F. Eicosanoids: eicosanoid antagonists. Online PowerPoint presentation. [http://www.pharmacology.ubc.ca/handouts/ Prostanoids%20and%20Leukotrienes.ppt258,1,Slide] (accessed August 2007)
6. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001;110(Suppl 3A):28S-32S
7. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. NEJM 2005;352:1071-80
8. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9
9. Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J 2005;118:U1684
10. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8
11. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. NEJM 2005;352:1092-102
12. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44
13. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:266-74
14. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006;92:1610-5
15. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366
16. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
17. Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006;24:1457-69
18. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007;167:394-9
19. Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007;66:764-70
20. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004;109:3000-6
21. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17
22. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-17
23. Cheema AA. Should people on aspirin avoid ibuprofen? A review of the literature. Cardiol Rev 2004;12:174-6
24. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95:2218-24
25. Medicines and Healthcare Products Regulatory Authority (MHRA). Cardiovascular Safety of Non-Steroidal Anti-inflammatory Drugs Overview of key data, 2005. [http://www.mhra.gov.uk/home/idcplg?IdcService= SS_GET_PAGE&nodeId=227] (accessed August 2007)
26. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42
27. Clinical Trials.gov. PRECISION: prospective randomized evaluation of celecoxib integrated safety vs ibuprofen or naproxen: Health Authority: United States: Food and Drug Administration, 2006. [http://www.clinicaltrials.gov/ct/ gui/show/NCT00346216?order=12] (accessed August 2007)